Jiangsu Jibeier Pharmaceutical (688566)2024-09-19 10:44Group 1: Company Overview - Jiangsu Jibeier Pharmaceutical Co., Ltd. is the only company producing Likujun tablets domestically and internationally, establishing a significant market position in the leukocyte-promoting drug sector [2][3]. - The company has developed a robust R&D platform focusing on compound formulations, deuterated drugs, and liposome drug technologies, leading to a pipeline of innovative drugs [6]. Group 2: Product Highlights - Likujun tablets are primarily used for preventing and treating leukopenia and thrombocytopenia, showing significant efficacy in patients undergoing radiation and chemotherapy [3][5]. - The raw material quality of Likujun has been enhanced to over 99% after systematic secondary development, ensuring product safety and clinical efficacy [4]. Group 3: Market Performance - In the first half of 2024, sales revenue for Niqunlor tablets reached 65.82 million yuan, representing a year-on-year increase of 90.03% [5]. - The market for Niqunlor tablets, which target hypertension with concurrent tachycardia, is substantial, with over one-third of hypertension patients also experiencing elevated heart rates [5]. Group 4: Future Prospects - The company is actively expanding the application of Likujun tablets in oncology, having been included as a recommended medication for malignant tumors in a clinical path book published in May 2022 [5]. - Ongoing clinical trials for new drugs JJH201501 (antidepressant) and JJH201601 (anticancer) are progressing, with JJH201501 in Phase III trials and JJH201601 in Phase I trials [6].